Esophagus Cancer
110
29
37
35
Key Insights
Highlights
Success Rate
85% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
5.5%
6 terminated out of 110 trials
85.4%
-1.1% vs benchmark
5%
5 trials in Phase 3/4
20%
7 of 35 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 35 completed trials
Clinical Trials (110)
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)
A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies
Proton Beam Therapy in the Treatment of Esophageal Cancer
Mayo Clinic Upper Digestive Disease Survey
Multimodal Deep Learning for Predicting Treatment Response to Neoadjuvant Chemoimmunotherapy in Esophageal Cancer
Retrospective Review of Esophageal Cancer at MSKCC
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Clinical Study on Noninvasive Evaluation of Ivonescimab Antibody Distribution and Expression in Esophageal Cancer Patients by 89Zr-AK112 PET Imaging
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
Imaging and Blood-Based Biomarkers for the Evaluation of Early Signs of Myocardial Injury After Thoracic Radiation Therapy
Target-specific immunoPET Imaging of Digestive System Carcinoma
A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma
Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer
Endoluminal Vacuum Therapy to Prevent Anastomotic Leakage After Esophagectomy Due to Esophageal Cancer
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer
Enhanced Assistance During Radiotherapy for Unmet Essential Needs